Powder: -20°C for 3 years | In solvent: -80°C for 1 year
O-1602 is a novel GPR55 agonist, an atypical cannabinoid associated with the central nervous system and obesity, and is a candidate compound for the treatment of cystitis.O-1602 promotes hepatic steatosis through GPR55 and PI3 kinase / Akt / SREBP-1c signalling in mice.O-1602 induces, in a GPR3-independent manner, in Hep55B cells with elevated intracellular calcium.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 155.00 | |
25 mg | In stock | $ 313.00 | |
50 mg | In stock | $ 493.00 | |
100 mg | In stock | $ 718.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 107.00 |
Description | O-1602 is a novel GPR55 agonist, an atypical cannabinoid associated with the central nervous system and obesity, and is a candidate compound for the treatment of cystitis.O-1602 promotes hepatic steatosis through GPR55 and PI3 kinase / Akt / SREBP-1c signalling in mice.O-1602 induces, in a GPR3-independent manner, in Hep55B cells with elevated intracellular calcium. |
Synonyms | O1602, O 1602 |
Molecular Weight | 258.36 |
Formula | C17H22O2 |
CAS No. | 317321-41-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25.84 mg/mL (100 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
O-1602 317321-41-8 GPCR/G Protein Membrane transporter/Ion channel Metabolism Calcium Channel Cannabinoid Receptor O1602 O 1602 inhibitor inhibit